In this study, we showed that TCF3-PBX1 positive pediatric BCP-ALL patients treated according to the JACLS ALL02 and CCLSG ALL2004 protocol had favorable outcomes similar to those reported in western countries (Table 2) 2,4–6. This evidence concerns the gene TCF3 and acute lymphoblastic leukemia.